Established medications are not a direct pharmacological match for ibogaine—and they do not need to be for comparison to be useful.
For alcohol use disorder, approved and commonly used medications are generally described through more specific clinical indications and trial programs. Naltrexone is often framed around opioid receptor blockade; acamprosate is associated with glutamatergic and GABA-related signaling; disulfiram works through alcohol metabolism rather than by changing alcohol reward circuitry. Ibogaine’s proposed activity is broader and less clinically settled.
That contrast is important: multimodal pharmacology can generate hypotheses, but it can also make cause and effect harder to isolate. A practical distinction between the resource topics covered across this site and a treatment claim is that explanations here stay tied to what is known, what is inferred and what has not yet been tested adequately in people with alcohol use disorder.
“Mechanistic plausibility is a reason to study a question—not a reason to assume the answer.”